AbbVie Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- AbbVie Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $9.00M, a 25.00% decline year-over-year.
- AbbVie Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $1.49B, a 54.94% increase year-over-year.
- AbbVie Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $3.00M, a 99.16% decline year-over-year.
- AbbVie Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $4.00M, a 76.47% decline year-over-year.
- AbbVie Inc. payments for repurchase of common stock for fiscal 2025 was $980.00M, a 42.62% decline from fiscal 2024.
- AbbVie Inc. payments for repurchase of common stock for fiscal 2024 was $1.71B, a 13.39% decline from fiscal 2023.
- AbbVie Inc. payments for repurchase of common stock for fiscal 2023 was $1.97B, a 32.62% increase from fiscal 2022.
- AbbVie Inc. payments for repurchase of common stock for fiscal 2022 was $1.49B, a 59.21% increase from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.50B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $1.49B 10-Q · filed 2026-05-08 | $1.51B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $980.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.33B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.35B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $961.00M 10-Q · filed 2026-05-08 | $1.34B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $358.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.71B 10-K · filed 2026-02-20 |
| 2024-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.35B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $1.34B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $1.32B 10-Q · filed 2025-05-09 | $1.34B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.97B 10-K · filed 2026-02-20 |
| 2023-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.97B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.97B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $1.96B 10-Q · filed 2024-05-03 | $1.97B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $1.49B 10-K · filed 2025-02-14 |
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.61B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.62B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $1.47B 10-Q · filed 2023-05-05 | $1.62B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $131.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $934.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.10B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.11B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $787.00M 10-Q · filed 2022-05-06 | $1.12B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $296.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $978.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $684.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $668.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $643.00M 10-Q · filed 2021-05-07 | $652.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $629.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.69B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $3.69B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $620.00M 10-Q · filed 2020-05-08 | $11.20B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $2.06B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $12.01B 10-K · filed 2021-02-19 |
| 2018-09-30 | $1.01B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $10.46B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $7.52B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $9.46B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $1.43B 10-Q · filed 2019-05-03 | $1.95B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $505.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.41B 10-K · filed 2020-02-21 |
| 2017-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $2.71B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.72B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $895.00M 10-Q · filed 2018-05-04 | $6.52B derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $1.81B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $6.03B 10-K · filed 2019-02-27 |
| 2016-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.47B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $3.81B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $6.46B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $409.00M 10-Q · filed 2017-05-05 | $7.65B derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $1.24B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $7.59B 10-K · filed 2018-02-16 |
| 2015-09-30 | $998.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $6.66B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $5.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $5.66B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $342.00M 10-Q · filed 2016-05-06 | $678.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $313.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $665.00M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $553.00M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $552.00M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $329.00M 10-Q · filed 2015-05-08 | $552.00M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $201.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $320.00M 10-K · filed 2016-02-19 |
| 2013-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2013-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | |
| 2013-03-31 | $97.00M 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |